AZN Tagrisso + Orpathys Hits SANOVO PFS in MET-High NSCLC

AstraZeneca’s Tagrisso (osimertinib) plus Orpathys (savolitinib) beat Tagrisso alone on progression-free survival (PFS) in the SANOVO Phase 3 trial, a 326-patient study partner HUTCHMED (HCM) ran entirely in China. The readout covers treatment-naive patients whose EGFR-mutant non-small cell lung cancer (NSCLC) also carries MET overexpression, a trait that shortens how long EGFR inhibitors alone keep tumors in check.

The combination met its primary endpoint with a statistically significant and, in the companies’ words, “highly clinically meaningful” PFS improvement in both the high-MET group (IHC 3+) and the wider intent-to-treat population (IHC 2+ and 3+). Overall survival, a secondary endpoint, trended favorably but is still maturing. AstraZeneca and HUTCHMED withheld the actual PFS figures, saying full data will come at a future medical meeting.

Savolitinib is an oral MET tyrosine-kinase inhibitor, and osimertinib is the third-generation EGFR inhibitor that anchors most EGFR-mutant lung cancer care. MET overexpression helps tumors sidestep EGFR blockade, so attacking both growth signals at once is the logic behind the all-oral pairing.

In the MET inhibitor class, Orpathys competes with Novartis’s capmatinib (Tabrecta) and Merck KGaA’s tepotinib (Tepmetko), both cleared for MET exon 14 skipping NSCLC. The SANOVO result is specific to the Tagrisso pairing, where savolitinib’s selectivity has let AstraZeneca and HUTCHMED run a series of trials across lines of therapy. For HUTCHMED, which co-developed savolitinib and shares economics with AstraZeneca, SANOVO extends a royalty stream already underpinned by SACHI and SAFFRON.

AZN closed at $162.47 on September 1. For a mega-cap drugmaker, a China readout rarely moves the stock, and this one is no exception.

The honest framing is that this is a China registration signal, not a near-term US catalyst. Both drugs are already FDA-approved, and the combination is already cleared in China for MET-amplified NSCLC after progression on an EGFR inhibitor, based on the SACHI trial. SANOVO pushes the pairing into the first line in China, where HUTCHMED will file with regulators. The US path is separate: AstraZeneca’s global SAFFRON trial tests the same combo in a later-line MET-driven setting, not first-line.

The real question is whether MET overexpression becomes a routine upfront biomarker. If it does, the addressable population for the all-oral combo widens well beyond the smaller MET-amplification group. Roughly 30-40% of Asian NSCLC patients carry EGFR mutations, and MET overexpression or amplification drives resistance in about a third who progress on a third-generation EGFR inhibitor. In the same EGFR lung cancer field, Cullinan’s zipalertinib awaits an FDA decision for exon 20 insertion mutations.

What to watch: the full PFS and safety data at the medical meeting, plus HUTCHMED’s China submission. Separately, AstraZeneca and Daiichi Sankyo announced EU approval of Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer.

What It Means for the Trade

The correct way to price this readout is as an option exercise, not a re-rating event. AZN at $162.47 does not trade on Chinese first-line lung cancer data, and HUTCHMED’s U.S.-listed shares carry the more direct exposure via the royalty and China economics. The value here is incremental in three layers: HUTCHMED gets a China first-line filing that extends savolitinib’s on-label window earlier in the treatment sequence; AstraZeneca gets free evidence that its Tagrisso anchoring strategy tolerates rational combinations — useful posture in a franchise it defends against a growing list of resistance-directed challengers; and the field gets another data point that dual blockade of EGFR plus MET is the answer to the third of EGFR-inhibitor patients whose tumors escape through the MET axis.

The withheld numbers are the thing to respect before the medical meeting. “Statistically significant and highly clinically meaningful” in a company press release is a floor, not a description — the market has learned to wait for the hazard ratio. The specific cut to scrutinize when data lands: the magnitude in the IHC 3+ high-MET group versus the IHC 2+ group, because the wider 2+/3+ population is where the commercial volume sits, and a benefit concentrated only in 3+ patients makes the biomarker-gated population too thin to justify routine upfront MET testing. The OS trend is the other number that decides whether this is a China label or a global strategy — PFS wins with immature OS routinely translate into label approvals but rarely into durable guideline dominance.

Mechanism and Trial Context

The biology is the cleanest part of the story. EGFR-mutant NSCLC treated with osimertinib develops resistance through identifiable bypass tracks, and MET signaling — via amplification or overexpression — is one of the most common. Running a selective MET inhibitor alongside the EGFR inhibitor from the start, rather than after progression, is the rational-preemption design, and SANOVO’s first-line structure is what distinguishes it from the SACHI trial that already cleared the post-progression combination in China. Savolitinib’s selectivity matters practically: dirtier MET inhibitors carry enough off-target toxicity that chronic combination dosing becomes untenable, and the ability to run savolitinib with osimertinib for years is what makes the upfront design feasible at all.

The competitive frame cuts both ways. Orpathys competes in the MET class with capmatinib and tepotinib, both approved in MET exon 14 skipping — a different patient population — but the real fight for the first-line EGFR-MET combination space will be decided by data quality and regulatory geography. A China-only first-line label gives HUTCHMED a defensible home-market position while the global SAFFRON trial runs in the later-line setting; a U.S. first-line path would require its own multiregional trial, which nobody has yet committed to publicly.

Risks and What Could Go Wrong

1. The full PFS data disappoints relative to the press-release framing — a modest hazard ratio with a heavy toxicity price from chronic MET inhibition changes the story from “combination strategy” to “niche biomarker play.”
2. OS matures flat: with crossover and post-progression MET therapy, a survival curve that doesn’t separate caps the combination’s guideline relevance regardless of PFS.
3. China pricing and access: HUTCHMED’s revenue math depends on NMPA reimbursement dynamics for a combination whose incremental cost over Tagrisso alone must be justified by an as-yet-unpublished endpoint.
4. The multiregional bar: FDA precedent demands diverse global populations; SANOVO’s China-only design means none of this data directly supports a U.S. first-line filing, and the gap between the two markets stays wide until someone funds the bridging trial.

Position read: HCM is the tradeable version of this catalyst; AZN is the footnote. Wait for the hazard ratio before adding on the readout — China-trial press-release framing has a history of compressing at medical meetings.